Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently shared its Q4 2024 and FY ...

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug ...

We found immune infiltrating cells associated with the core gene clusters ... inhibits breast cancer by suppressing the expression of PLK1 in breast cancer cells. This leads to the downregulation of ...

Immune cells that eat bacteria in the body don't stash them in specialized compartments as once thought, but turn them into critical nutrients that build proteins, create energy and keep the cells ...

Bacteria consumed by immune cells become part of the cell Date: February 26, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Immune cells that eat bacteria in the body don't ...